JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Radiology
PUBLISHED: 04-02-2014
Show Abstract
Hide Abstract
To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC).
Related JoVE Video
Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis.
Hepatol. Res.
PUBLISHED: 01-14-2014
Show Abstract
Hide Abstract
Patients with hepatocellular carcinoma (HCC) who receive an initial full dose of sorafenib (800?mg/day) often require a decreased dose (400?mg/day) or discontinuation of therapy because of severe adverse events. We conducted a retrospective analysis of patients with HCC to compare the safety and efficacy of full- to half-dose sorafenib.
Related JoVE Video
Efficacy of chemoembolization for recurrent HCC after curative ablation therapy.
Hepatogastroenterology
PUBLISHED: 09-26-2013
Show Abstract
Hide Abstract
Transarterial chemoembolization (TACE) is a widely applied standard treatment option for treatment-naïve patients with multifocal hepatocellular carcinoma (HCC). However, the treatment strategy in patients with multi-nodular recurrences has not been well addressed. This retrospective cohort study aimed to evaluate the efficacy of TACE for recurrent HCC.
Related JoVE Video
Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
Eur J Radiol
PUBLISHED: 06-20-2013
Show Abstract
Hide Abstract
We evaluated the contrast-enhanced ultrasonography (US) imaging features of early hepatocellular carcinomas (HCCs) and compared these findings with those obtained using contrast-enhanced computed tomography (CT).
Related JoVE Video
High-intensity focused ultrasound ablation assisted using color Doppler imaging for the treatment of hepatocellular carcinomas.
Abdom Imaging
PUBLISHED: 06-04-2013
Show Abstract
Hide Abstract
We evaluated the usefulness of color Doppler flow imaging to compensate for the inadequate resolution of the ultrasound (US) monitoring during high-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma (HCC).
Related JoVE Video
Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma.
Anticancer Res.
PUBLISHED: 03-14-2013
Show Abstract
Hide Abstract
This study aimed to evaluate the fucosylated fraction of alpha-fetoprotein (AFP-L3) as a marker of early hepatocellular carcinoma (HCC).
Related JoVE Video
Hepatic failure in pregnancy successfully treated by online hemodiafiltration: Chronic hepatitis B virus infection without viral genome mutation.
Hepatol. Res.
PUBLISHED: 02-01-2013
Show Abstract
Hide Abstract
A 23-year-old nulliparous woman, a hepatitis B virus (HBV) carrier with stable liver functions, presented with exacerbation of viral replication (HBV DNA level >9.0?log copies/mL) in gestational week 26. During the subsequent follow up without antiviral therapy, she was hospitalized with progression to hepatic failure in gestational week 35. Following initiation of antiviral therapy with lamivudine, emergent cesarean delivery was conducted for fetal safety. Liver atrophy and persistent hepatic encephalopathy (stage 2) necessitated artificial liver support (ALS) involving online hemodiafiltration (HDF) and plasma exchange. She regained full consciousness after the sixth online HDF session. ALS was terminated after the seventh online HDF session. On day 33 of hospitalization, she was discharged home without sequelae. Genetic analysis of the HBV strain isolated from her serum showed that this strain had genotype C. Direct full-length sequencing identified no known mutations associated with fulminant hepatitis B. HBV-related hepatic failure observed in the present case might have been related to perinatal changes in the host immune response.
Related JoVE Video
Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Eur J Radiol
PUBLISHED: 01-17-2013
Show Abstract
Hide Abstract
We evaluated the efficacy of contrast-enhanced ultrasonography (US), compared with contrast-enhanced computed tomography (CT), for early assessments after transarterial chemoembolization (TACE) for the treatment of hypervascular hepatocellular carcinoma (HCC) lesions.
Related JoVE Video
Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C.
Hepatol. Res.
PUBLISHED: 01-02-2013
Show Abstract
Hide Abstract
Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus ribavirin combination therapy for hepatitis C virus genotype 1. However, few studies have reported its effects on therapy for genotype 2. We aimed to examine the effects of IL-28B gene polymorphism on treatment response in hepatitis C virus genotype 2 patients.
Related JoVE Video
Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma.
Eur J Radiol
PUBLISHED: 09-07-2011
Show Abstract
Hide Abstract
We evaluated the efficacy of fusion imaging, which fuses contrast-enhanced ultrasonography images with arterial-phase, contrast-enhanced CT images as a reference on a single screen in real time, for the evaluation of the effectiveness of radiofrequency ablation for treatment of hypervascular hepatocellular carcinoma.
Related JoVE Video
Hyperecho in ultrasound images during high-intensity focused ultrasound ablation for hepatocellular carcinomas.
Eur J Radiol
PUBLISHED: 05-31-2011
Show Abstract
Hide Abstract
High-intensity focused ultrasound (HIFU) is a noninvasive method that can cause complete coagulation necrosis without requiring the insertion of any instruments. The hyperechoic grayscale change (hyperechoic region) is used as a sign that the treated lesion has been completely coagulated. The purpose of this study was to evaluate the first hyperechoic region during treatment using HIFU ablation according to various conditions, such as the sonication power, the depth of the tumor from the surface of the skin, and the shield rate. HIFU treatment was performed in 20 patients. The HIFU system (Chongqing Haifu Tech, Chongqing, China) was used under ultrasound guidance. Complete coagulation was achieved in 17 cases. Hyperechoic region were detected after HIFU ablation in 17 patients. The size of the hyperechoic region at a depth of >50 mm was significantly smaller than that at a depth of ?50 mm. The number and power of the sonications for areas at a depth of >50 mm were significantly larger than those for areas at a depth of ?50 mm. The number and power in cases with a shield rate of 31-60% were significantly larger than those in cases with a shield rate of 0-30%. When the shield rate was 0%, a hyperechoic region occurred, even when a maximum sonication power was not used. In all three cases with tumors located at a depth of greater than 70 mm and a shield rate of larger than 60%, a hyperechoic region was not seen. In conclusion, hyperechoic regions are easy to visualize in cases with tumors located at a depth of ?50 mm or shield rates of 0-30%.
Related JoVE Video
Novel Lens culinaris agglutinin-reactive fraction of ?-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low ?-fetoprotein concentrations.
Int. J. Clin. Oncol.
PUBLISHED: 03-12-2011
Show Abstract
Hide Abstract
Lens culinaris agglutinin-reactive fraction of ?-fetoprotein (AFP-L3) is a specific marker used to detect hepatocellular carcinoma (HCC). However, its clinical utility is not sufficient in patients with low total AFP concentrations because of limitations in instrument sensitivity. Recent advances have led to the introduction of a highly sensitive AFP-L3% assay (sensitive AFP-L3%), provided by a novel on-chip, liquid-phase binding assay. This cross-sectional study was conducted to evaluate the clinical significance of the sensitive AFP-L3% in determining HCC recurrence in patients with low total AFP concentrations.
Related JoVE Video
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib.
Hepatol. Res.
PUBLISHED: 02-23-2011
Show Abstract
Hide Abstract
Aim:? Sorafenib is approved for the treatment of advanced hepatocellular carcinoma (HCC) in Japan; however, its tolerability and efficacy in elderly patients with HCC have not been clarified. We aimed to evaluate the tolerability and efficacy of sorafenib with increasing age. Methods:? As part of a retrospective, multicenter cohort study conducted between May 2009 and February 2010, patients with advanced HCC received 400?mg sorafenib twice daily (standard dosage) or once daily (half-dosage) until disease progression or treatment intolerance. Results:? The mean age of the enrolled patients (n?=?76) was 70.3?years, and 24 of them were ?75?years old. The prognostic factors for survival were age?
Related JoVE Video
Usefulness of US-CT 3D dual imaging for the planning and monitoring of hepatocellular carcinoma treatment using HIFU.
Eur J Radiol
PUBLISHED: 02-08-2011
Show Abstract
Hide Abstract
We evaluated the safety and usefulness of high-intensity focused ultrasound (HIFU) assisted by ultrasound-computed tomography three-dimensional (US-CT 3D) dual imaging for the treatment of hepatocellular carcinoma (HCC).
Related JoVE Video
Findings of multidetector row computed tomography of HCCs treated by HIFU ablation.
Eur J Radiol
PUBLISHED: 01-24-2011
Show Abstract
Hide Abstract
We evaluated the efficacy of high-intensity focused ultrasound (HIFU) ablation for hepatocellular carcinoma (HCC), and a long-term study by follow-up multidetector-row computed tomography (CT) was conducted to evaluate the changes occurring in the treatment area following the HIFU ablation.
Related JoVE Video
Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients.
Antivir. Ther. (Lond.)
PUBLISHED: 12-15-2010
Show Abstract
Hide Abstract
HCV is the main causative agent of chronic liver disease, which could progress to liver cirrhosis and hepatocellular carcinoma. By using a recently developed genome-length HCV RNA replication reporter assay system, we found that hydroxyurea (HU), an inhibitor of DNA synthesis, inhibited HCV RNA replication.
Related JoVE Video
Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Jpn. J. Clin. Oncol.
PUBLISHED: 08-05-2010
Show Abstract
Hide Abstract
We retrospectively evaluated the antitumor effect, survival and toxicities of hepatic arterial infusion therapy using a fine powder formulation of cisplatin (cisplatin powder) in hepatocellular carcinoma patients with portal vein tumor thrombosis.
Related JoVE Video
Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model.
J Vasc Interv Radiol
PUBLISHED: 05-20-2010
Show Abstract
Hide Abstract
To assess the extended effects of transcatheter arterial embolization with iodized oil and gelatin sponge on liver histopathologic changes in radiofrequency (RF)-ablated zones and the surrounding liver parenchyma in a pig model.
Related JoVE Video
Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies.
World J. Gastroenterol.
PUBLISHED: 05-05-2010
Show Abstract
Hide Abstract
To differentiate focal liver lesions based on enhancement patterns using three-dimensional ultrasonography (3D US) with perflubutane-based contrast agent.
Related JoVE Video
C-arm cone beam CT for hepatic tumor ablation under real-time 3D imaging.
AJR Am J Roentgenol
PUBLISHED: 04-23-2010
Show Abstract
Hide Abstract
We describe our experience with the application of a novel technology in which fluoroscopy and 3D imaging from C-arm cone beam CT systems are combined with integrated navigation software.
Related JoVE Video
Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Arch. Virol.
PUBLISHED: 03-05-2010
Show Abstract
Hide Abstract
Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.
Related JoVE Video
Contrast enhanced ultrasound of hepatocellular carcinoma.
World J Radiol
PUBLISHED: 02-10-2010
Show Abstract
Hide Abstract
Sonazoid (Daiichi Sankyo, Tokyo, Japan), a second-generation of a lipid-stabilized suspension of a perfluorobutane gas microbubble contrast agent, has been used clinically in patients with liver tumors and for harmonic gray-scale ultrasonography (US) in Japan since January 2007. Sonazoid-enhanced US has two phases of contrast enhancement: vascular and late. In the late phase of Sonazoid-enhanced US, we scanned the whole liver using this modality at a low mechanical index (MI) without destroying the microbubbles, and this method allows detection of small viable hepatocellular carcinoma (HCC) lesions which cannot be detected by conventional US as perfusion defects in the late phase. Re-injection of Sonazoid into an HCC lesion which previously showed a perfusion defect in the late phase is useful for confirming blood flow into the defects. High MI intermittent imaging at 2 frames per second in the late phase is also helpful in differentiation between necrosis and viable hypervascular HCC lesions. Sonazoid-enhanced US by the coded harmonic angio mode at a high MI not only allows clear observation of tumor vessels and tumor enhancement, but also permits automatic scanning with Sonazoid-enhanced three dimensional (3D) US. Fusion images combining US with contrast-enhanced CT or contrast-enhanced MRI have made it easy to detect typical or atypical HCC lesions. By these methods, Sonazoid-enhanced US can characterize liver tumors, grade HCC lesions histologically, recognize HCC dedifferentiation, evaluate the efficacy of ablation therapy or transcatheter arterial embolization, and guide ablation therapy for unresectable HCC. This article reviews the current developments and applications of Sonazoid-enhanced US and Sonazoid-enhanced 3D US for diagnosing and treating hepatic lesions, especially HCC.
Related JoVE Video
Sonazoid-enhanced ultrasonography for evaluation of the enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index.
J Ultrasound Med
PUBLISHED: 03-27-2009
Show Abstract
Hide Abstract
The purpose of this study was to evaluate the enhancement patterns of focal liver tumors in the late phase of Sonazoid-enhanced ultrasonography by intermittent imaging with a high mechanical index (MI).
Related JoVE Video
Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT.
Radiology
PUBLISHED: 02-12-2009
Show Abstract
Hide Abstract
To investigate the potential application of contrast material-enhanced three-dimensional (3D) ultrasonography (US), as compared with contrast-enhanced 3D computed tomography (CT), for characterization of focal liver tumors.
Related JoVE Video
Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study.
Eur J Radiol
Show Abstract
Hide Abstract
This study evaluated the safety and efficacy of using radiofrequency ablation combined with transarterial chemoembolization to treat hepatocellular carcinoma in a subcapsular location, given the increased risk of complications when using radiofrequency ablation alone.
Related JoVE Video
[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Gan To Kagaku Ryoho
Show Abstract
Hide Abstract
Some clinical studies confirmed the efficacy and safety of sorafenib in advanced hepatocellular carcinoma(HCC), for which the standard initial dose is 400 mg twice daily. However, it is unclear whether this dosage is tolerable for patients with a low body surface area(BSA). We retrospectively analyzed the difference in efficacy and safety of sorafenib between patients with low BSA and high BSA.
Related JoVE Video
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Anticancer Res.
Show Abstract
Hide Abstract
No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC).
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.